@article{015bdd9ed7834bada4a979796f9705fb,
title = "Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites",
abstract = "Aim: The first Plan-Do-Study-Act cycle for the Veterans Affairs Pharmacogenomic Testing for Veterans pharmacogenomic clinical testing program is described. Materials & methods: Surveys evaluating implementation resources and processes were distributed to implementation teams, providers, laboratory and health informatics staff. Survey responses were mapped to the Consolidated Framework for Implementation Research constructs to identify implementation barriers. The Expert Recommendation for Implementing Change strategies were used to address implementation barriers. Results: Survey response rate was 23-73% across personnel groups at six Veterans Affairs sites. Nine Consolidated Framework for Implementation Research constructs were most salient implementation barriers. Program revisions addressed these barriers using the Expert Recommendation for Implementing Change strategies related to three domains. Conclusion: Beyond providing free pharmacogenomic testing, additional implementation barriers need to be addressed for improved program uptake. ",
keywords = "Plan-Do-Study-Act cycles, Veterans, Veterans Affairs, genetic testing, implementation barriers, pharmacogenomics, precision medicine, quality improvement",
author = "Dong, {Olivia M.} and Roberts, {Megan C.} and Wu, {R. Ryanne} and Voils, {Corrine I.} and Nina Sperber and Gavin, {Kara L.} and Jill Bates and Catherine Chanfreau-Coffinier and Michael Naglich and Kelley, {Michael J.} and Vassy, {Jason L.} and Peruvemba Sriram and Heise, {C. William} and Salvador Rivas and Maria Ribeiro and Chapman, {Jennifer G.} and Deepak Voora",
note = "Funding Information: The authors thank Laurence Meyer, Michael Icardi, Neil Spector, Natasha Petry, Jordan Baye, April Schultz, Amanda Massmann, Joel Van Heukelom, Joanne Allen, Linda Berg, Jahala Collins and Douglas Ball for their support. The authors thank the following site coordinators for the logistical implementation of the PHASER program at local VA sites: Omerea Solis, Lorraine Sieverson, Charles Brunette, Brian Walker, Ashley Antwi, Alicia Harrison, Tarulata Patel and Mark Lund. This material is based upon work supported in part by the Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT) (CIN 13-410) at the Durham VA Health Care System. Funding Information: The PHASER program is funded through a donation to the Department of Veterans Affairs from Sanford Health and D San-ford, which provides salary support for D Voora, RR Wu, JG Chapman, J Bates, M Naglich and C Chanfreau-Coffinier. OM Dong is supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number 5T32HG008955-03. CI Voils is funded by Research Career Scientist award RCS 14-443 from the Department of Veterans Affairs Health Services Research & Development service. CW Heise is supported by the Flinn Foundation. D Voora is a member of the Sanford Health Imagenetics External Advisory Board and on the advisory board for Optum Labs for which he receives compensation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Funding Information: The PHASER program is funded through a donation to the Department of Veterans Affairs from Sanford Health and D Sanford, which provides salary support for D Voora, RR Wu, JG Chapman, J Bates, M Naglich and C Chanfreau-Coffinier. OM Dong is supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number 5T32HG008955-03. CI Voils is funded by Research Career Scientist award RCS 14-443 from the Department of Veterans Affairs Health Services Research & Development service. CW Heise is supported by the Flinn Foundation. D Voora is a member of the Sanford Health Imagenetics External Advisory Board and on the advisory board for Optum Labs for which he receives compensation. Publisher Copyright: {\textcopyright} 2021 Future Medicine Ltd.",
year = "2021",
month = nov,
doi = "10.2217/pgs-2021-0089",
language = "English (US)",
volume = "22",
pages = "1121--1133",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "17",
}